A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer - Trial NCT06278493
Access comprehensive clinical trial information for NCT06278493 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and is currently Completed. The study focuses on Pancreatic Cancer. Target enrollment is 34 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 1/2
Aug 23, 2018
May 01, 2023
Primary Outcome
Dose limiting toxicity (DLT),Maximum tolerated dose (MTD)
Summary
This is a clinical study to observe the tolerance and primary efficacy of AL2846 capsules
 combined with Gemzar injection in patients with pancreatic cancer, and to determine the
 recommended dosage and administration method for subsequent clinical studies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06278493
Non-Device Trial